Tempest Therapeutics (NASDAQ:TPST) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Tempest Therapeutics (NASDAQ:TPST) to a sell rating in a research report sent to investors on Saturday,Wall Street Zen reports.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Tempest Therapeutics in a research report on Monday, July 13th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Tempest Therapeutics currently has a consensus rating of “Reduce”.

Tempest Therapeutics Price Performance

Tempest Therapeutics stock opened at $0.74 on Friday. The stock has a market cap of $12.54 million, a PE ratio of -0.17 and a beta of -1.73. The stock’s fifty day moving average is $0.95 and its two-hundred day moving average is $1.28. Tempest Therapeutics has a 1-year low of $0.74 and a 1-year high of $12.23.

Tempest Therapeutics (NASDAQ:TPST) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by ($0.04). On average, research analysts expect that Tempest Therapeutics will post -0.83 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Tempest Therapeutics stock. Sabby Management LLC bought a new stake in Tempest Therapeutics, Inc. (NASDAQ:TPST) during the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 178,592 shares of the company’s stock, valued at approximately $513,000. Tempest Therapeutics comprises about 0.7% of Sabby Management LLC’s holdings, making the stock its 7th largest position. Sabby Management LLC owned approximately 3.62% of Tempest Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 22.52% of the company’s stock.

About Tempest Therapeutics

Tempest Therapeutics, Inc is a clinical-stage biotechnology company focused on developing small-molecule medicines for cancer. The company’s research combines tumor-targeted immune activation with approaches designed to disrupt tumor metabolism, with the goal of stimulating the immune system within the tumor microenvironment while limiting effects on healthy tissue.

Tempest’s pipeline has included TPST-1120, an oral, selective antagonist of peroxisome proliferator-activated receptor alpha (PPARα).